Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

YM BioSciences Inc. (YMB)

  Print      Mail a friend

Thursday 17 September, 2009

YM BioSciences Inc.



    YM Enrolls First Patients in Multinational Randomized, Double-Blind Brain
    Metastases Trial
    MISSISSAUGA, Sept. 17 /CNW/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM,
AIM:YMBA), a life sciences product development company that identifies and
advances a diverse portfolio of promising cancer-related products at various
stages of development, today reported that nimotuzumab has been approved for
marketing in Mexico. YM BioSciences also announced that it has enrolled the
first two patients in its randomized, double-blind trial evaluating
nimotuzumab in patients with brain metastases from non-small-cell lung cancer
    "Mexico is the 21st country to have approved nimotuzumab for marketing
and, while YM's license for major market territories for nimotuzumab does not
include Mexico, this approval reflects the growing recognition throughout much
of the world of the value to patients of our drug and the progress being made
in its commercialization," said David Allan, Chairman and CEO of YM
BioSciences. "As part of YM's registration strategy for nimotuzumab, we were
also pleased to report the opening of this second of two randomized,
double-blind trials that YM is conducting in Canada and which are both now
being expanded internationally."
    Nimotuzumab is a humanized monoclonal antibody that targets the epidermal
growth factor receptor (EGFR), licensed to YM's majority-owned subsidiary,
CIMYM BioSciences Inc., by CIMAB S.A., and developed at the Center of
Molecular Immunology in Cuba. Nimotuzumab is approved in two of the countries
in YM's territories. The drug has demonstrated efficacy in clinical trials
without producing the numerous and severe toxicities observed with the other
marketed EGFR-targeting drugs. Mexican regulatory authorities have approved
nimotuzumab for the treatment of squamous cell carcinoma of the head and neck
(SCCHN), adult glioma and pediatric glioma. The approval was granted to
Laboratorios PiSA in Guadalajara, Mexico and nimotuzumab will be
commercialized under the name VECTHIX(R).

    First patients enrolled in multinational randomized, double-blind brain
    metastases trial
    YM BioSciences recently enrolled and treated the first two patients in
its multinational randomized, double-blind trial evaluating nimotuzumab plus
whole-brain radiation therapy (WBRT) to WBRT alone in patients with brain
metastases from NSCLC. The trial is designed enroll approximately 88 patients
over twelve months followed by a twelve-month follow-up period and will likely
include 12 investigational centers in Canada plus additional centers in other
countries. The patients were enrolled at the L'Hôpital Maisonneuve-Rosemont in
Montreal, Canada.
    Nimotuzumab (200 mg IV infusions) will be administered weekly during
radiotherapy and following radiotherapy until disease progression,
unacceptable toxicity or at the discretion of the physician. Radiotherapy will
consist of 30 Gy, in 10 fractions of 3 Gy/day. Patients will be assessed by
laboratory tests, imaging studies, standardized neurologic examination, and
neurologic symptoms. The primary efficacy endpoint is intracranial disease
progression over six months. The secondary endpoints are overall survival
(OS); time to neurologic progression (TNP) or death with evidence of
neurologic progression; OS rate at six months; time to intracranial disease
progression; and time to overall progression.
    "This randomized, double-blinded, multicentric trial was based on a
randomized pilot open-label trial from which encouraging, preliminary results
were presented at the EORTC-NCI-AACR "Molecular Targets and Cancer
Therapeutics" meeting held on October 21-24, 2008 in Geneva. YM is preparing
to imminently open the first international centers on both this and the
ongoing palliative NSCLC randomized trial. In this trial, as with the others
being conducted by YM, extensive samples are being collected and stored in
anticipation of a comprehensive program of translational analysis," said Dr.
Leonardo Viana Nicacio, YM's Director of Clinical Affairs.
    Nimotuzumab is reported to have been has been administered to more than
5,000 patients worldwide and is currently in 32 trials internationally of
which 11 are being conducted by YM and its four licensees. Three of the latter
are Phase III trials, including one being conducted by the internationally
recognized National Cancer Center of Singapore, which selected nimotuzumab
over the alternative antibodies because of its benign side effect profile.
Nimotuzumab is also available on a compassionate use basis in the US for
children with pediatric glioma and is designated an Orphan Drug for adult and
pediatric glioma by the FDA as well as the EMEA for Europe.

    About YM BioSciences

    YM BioSciences Inc. is a life sciences product development company that
identifies and advances a diverse portfolio of promising cancer-related
products at various stages of development. The Company is currently developing
two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized
Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of
free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical
trial expertise and a diversified business model designed to reduce risk while
advancing clinical products toward international approval, marketing and

    This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that nimotuzumab will continue to demonstrate a competitive
safety profile in ongoing and future clinical trials; that AeroLEF(R) will
continue to generate positive efficacy and safety data in future clinical
trials; and that YM and its various partners will complete their respective
clinical trials within the timelines communicated in this release. We
undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or

For further information: Enquiries: James Smith, the Equicom Group Inc., Tel.
(416) 815-0700 x 229, Email: jsmith(at); Thomas Fechtner, the
Trout Group LLC, Tel. (646) 378-2931, Email: tfechtner(at);
Nominated Adviser, Canaccord Adams Limited, Ryan Gaffney, Tel. +44 (0)20 7050


a d v e r t i s e m e n t